Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
暂无分享,去创建一个
J. Furuse | T. Takayama | K. Yamao | T. Kinoshitá | K. Uesaka | Shinichirou Takahashi | N. Gotohda | M. Konishi | D. Nobuoka | T. Nakagohri | K. Nakachi | H. Ishii | S. Mizuno | T. Nakatsura | T. Yoshikawa | Y. Sawada | H. Shirakawa | Yutaka Motomura | T. Kuronuma
[1] Y. Nishimura,et al. Usefulness of the Novel Oncofetal Antigen Glypican-3 for Diagnosis of Hepatocellular Carcinoma and Melanoma , 2005, BioDrugs.
[2] F. Kikkawa,et al. Glypican‐3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma , 2011, Cancer science.
[3] M. Itkin,et al. Expansion of interferon-gamma-producing multifunctional CD4+ T-cells and dysfunctional CD8+ T-cells by glypican-3 peptide library in hepatocellular carcinoma patients. , 2011, Clinical immunology.
[4] Yukie Tanaka,et al. HLA‐A2‐restricted glypican‐3 peptide‐specific CTL clones induced by peptide vaccine show high avidity and antigen‐specific killing activity against tumor cells , 2011, Cancer science.
[5] Masao Honda,et al. Comparative analysis of various tumor‐associated antigen‐specific t‐cell responses in patients with hepatocellular carcinoma , 2011, Hepatology.
[6] S. Morita,et al. Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib , 2011, Hepatology research : the official journal of the Japan Society of Hepatology.
[7] T. Kinoshitá,et al. Postoperative serum α-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma , 2010 .
[8] Riccardo Lencioni,et al. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.
[9] M. Manns,et al. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma , 2010, BMC Cancer.
[10] Y. Kondo,et al. Branched chain amino acids enhance the maturation and function of myeloid dendritic cells ex vivo in patients with advanced cirrhosis , 2009, Hepatology.
[11] M. Kojima,et al. Glypican‐3 expression is correlated with poor prognosis in hepatocellular carcinoma , 2009, Cancer science.
[12] H. Aburatani,et al. Glypican-3 expression in clear cell adenocarcinoma of the ovary , 2009, Modern Pathology.
[13] T. Hasebe,et al. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. , 2009, International journal of oncology.
[14] D. Kerr,et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma , 2009, Hepatology.
[15] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[16] S. Paggi,et al. Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .
[17] M. Tsao,et al. Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma , 2008, Modern Pathology.
[18] Y. Nishimura,et al. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. , 2008, International journal of oncology.
[19] Zheng Zhang,et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. , 2007, Gastroenterology.
[20] A. Ribas,et al. A Phase I/II Trial Testing Immunization of Hepatocellular Carcinoma Patients with Dendritic Cells Pulsed with Four α-Fetoprotein Peptides , 2006, Clinical Cancer Research.
[21] S. Senju,et al. Identification of HLA-A2- or HLA-A24-Restricted CTL Epitopes Possibly Useful for Glypican-3-Specific Immunotherapy of Hepatocellular Carcinoma , 2006, Clinical Cancer Research.
[22] S. Senju,et al. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. , 2006, Cancer research.
[23] A. Ribas,et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[25] Yusuke Nakamura,et al. Mouse Homologue of a Novel Human Oncofetal Antigen, Glypican-3, Evokes T-Cell–Mediated Tumor Rejection without Autoimmune Reactions in Mice , 2004, Clinical Cancer Research.
[26] K. Shirouzu,et al. Humoral Responses to Peptides Correlate with Overall Survival in Advanced Cancer Patients Vaccinated with Peptides Based on Pre-existing, Peptide-Specific Cellular Responses , 2004, Clinical Cancer Research.
[27] D. Speiser,et al. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination , 2004, Cancer Immunology, Immunotherapy.
[28] A. Ribas,et al. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] Wen Shi,et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. , 2003, Gastroenterology.
[30] Yusuke Nakamura,et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. , 2003, Biochemical and biophysical research communications.
[31] D. Morton,et al. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] D. Schlessinger,et al. Glypican-3 Expression in Wilms Tumor and Hepatoblastoma , 2001, Journal of pediatric hematology/oncology.
[33] D. Sinnett,et al. Expression of glypican 3 (GPC3) in embryonal tumors , 2000, International journal of cancer.
[34] Yasuo Ohashi,et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial , 2000, The Lancet.
[35] D. Adams,et al. Immunotherapy in hepatocellular carcinoma , 2000, The Lancet.
[36] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[37] 伊達 是志. DNA typing of the HLA-A gene : population study and identification of four new alleles in Japanese , 1998 .
[38] Y. Maehara,et al. DNA typing of HLA class I (HLA-A) and class II genes (HLA-DR, -DQ and -DP) in Japanese patients with gastric cancer. , 1997, Tissue antigens.
[39] J. Cormier,et al. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. , 1996, Cancer research.
[40] P. Krausa,et al. Genetic diversity of HLA-A2: evolutionary and functional significance. , 1996, Immunology today.
[41] T. Sasazuki,et al. DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese. , 1996, Tissue antigens.
[42] H. Niitani,et al. [Phase II study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.